Overall survival by SCT versus observation in first complete remission

Slides:



Advertisements
Similar presentations
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
Advertisements

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Copyright © 2017 American Academy of Pediatrics.
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study by Henk M. Lokhorst, Bronno van der.
 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.
Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,
by Sandra Luna-Fineman, Kevin M. Shannon, Susan K
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.
Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.
Protease inhibitors potentiate chemotherapy-induced neutropenia
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.
by J. Rodriguez, M. A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.
by Michael F. Leahy, and J. Harvey Turner
Natural course of HTLV-1 carriers with monoclonal proliferation of T lymphocytes (“pre-ATL”) in a 20-year follow-up study by Yoshitaka Imaizumi, Masako.
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.
Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia  Paul M. Armistead, Marcos.
Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.
Kaplan-Meier curves for overall survival (OS) probability.
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.
Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.
High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin.
• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.
Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.
(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.
Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.
Kaplan-Meier survival curve for unloader brace—Kaplan-Meier survival analysis demonstrated rapid conversion to TKR for the first 12 months, which then.
Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.
Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.
Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.
by Wendy Lim, Sara K. Vesely, and James N. George
Kaplan-Meier survival curves for non-fatal stroke or mortality based on IMRS categories among (A) women (p-trend
Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.
Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.
Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.
Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of
Rituximab immunotherapy: it’s getting personal
Kaplan-Meier plot of overall survival from the time of first dose of intrathecal interleukin-2 (IT IL-2) for all patients (A, n=43) and based on the extent.
Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.
Kaplan-Meier plots of the duration of continuous albuterol, time until q4 albuterol, and hospital LOS for each of the 4 treatment groups. Kaplan-Meier.
Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;
 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.
Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.
A and B, The ROC curves analyzing the sensitivity and specificity of the WHO grading system (I-IV) for the 1-year survival (A) and recurrence (B) show.
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,
by Jan J. Cornelissen, and Didier Blaise
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment by Waleed Ghanima, Bertrand Godeau,
Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant.
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Overall survival of systemic mastocytosis patients.
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.
Overall and recurrence-free survival.
Cold agglutinin disease
Outcomes in patients with PTCL
Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W
Presentation transcript:

Overall survival by SCT versus observation in first complete remission. Overall survival by SCT versus observation in first complete remission. Kaplan-Meier curves demonstrating overall survival (OS) by (A) use of SCT compared with observation among those in first complete remission (CR); OS by (B) those who were positive for central nervous system (CNS) involvement at the time of diagnosis compared with those who did and did not receive CNS-directed prophylaxis (PPX); and OS for (C) those with relapsed/refractory disease based on whether salvage therapy was administered (those who were not known to receive salvage therapy are included with those confirmed to have not received salvage therapy). Adam M. Petrich et al. Blood 2014;124:2354-2361 ©2014 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.